Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by Wide Margin; Guides FY23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $214.00 -0.3%
EPS Growth %: -22.5%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -22.5%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of ($0.07), $4.58 worse than the analyst estimate of $4.51. Revenue for the quarter came in at $972.13 million versus the consensus estimate of $975.18 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2023 EPS of $16.90-$17.86, versus the consensus of $18.00. Jazz Pharmaceuticals sees FY2023 revenue of $3.675-3.875 billion, versus the consensus of $3.76 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
